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Atrial ﬁbrillation (AF) is the most common cardiac rhythm disorder
[1]. There have been progressive increases in the worldwide prevalence
and incidence of AF with signiﬁcant effects on associated morbidity and
mortality [1]. Stroke is one of the most serious complications of AF, and
it has been conﬁrmed thatmost emboli come from the left atrial (LA) or
the left atrial appendage (LAA). Therefore, it was crucial to recognize the
patientswith AFwhowere on the increased risk for LA or LAA thrombus
formation. Multiple risk factors including age, hypertension, heart
failure (HF), enlarged left atrial diameter (LAD), and complex LAAmor-
phology [2] have been identiﬁed until now. However, our study found
that low high-density lipoprotein cholesterol (HDL-C) in patients with
non-valvular AF was a risk factor for LA or LAA thrombus formation.
A total of 188 consecutive patients (age 60.88 ± 9.63 years, [29–78
years], 108 men) with non-valvular AF who were admitted in our
department for radiofrequency catheter ablation (RFCA) from January
2008 to June 2014 were enrolled. The patients with severe stroke
complications, acute HF, malignant tumor and other disease unsuitabil-
ity for RFCA were excluded from our study. All baseline clinical charac-
teristics, laboratory examinations, transthoracic echocardiogram (TTE)
parameters and transesophageal echocardiography (TEE) parameters
were carefully recorded. We divided all the patients into thrombus
group and non-thrombus group according to whether embolus was
observed from TEE. CHADS2 score was calculated for each patient by
assigning one point each for congestive HF, hypertension, age ≥ 75
years, and diabetes mellitus, and two points for a previous stroke or
transient ischemic attack (TIA).
Baseline characteristics of our study population were shown in
Table 1. There were altogether 39 (20.7%) patients found embolus in
LA or LAA, and the levels of HDL-C in the patients from the thrombus
group was signiﬁcantly lower than the non-thrombus group (0.98 ±
0.22 vs. 1.15 ± 0.31, P = 0.001). Patients with LA or LAA thrombus
tended to be older, have a higher CHADS2 score and an increased
prevalence of previous stroke or TIA, peripheral vascular disease and
persistent or permanent AF than those from the non-thrombus group.
Compared with the non-thrombus group, LAD was increased
(44.35 ± 6.17 mm vs. 39.85 ± 5.41 mm, P b 0.001) and left ventricular
ejection fraction (LVEF) was decreased (54.54% ± 7.22% vs. 58.88% ±
6.80%, P b 0.001) in the thrombus group.Multivariate logistic regression
analysis showed that low levels of HDL-C (OR, 0.053, 95% CI: 0.008–http://dx.doi.org/10.1016/j.ijcme.2015.01.001
2214-7624/© 2015 Published by Elsevier Ireland Ltd. This is an open access article under the C0.330, P = 0.002), LAD (OR, 1.113, 95% CI: 1.023–1.210, P = 0.013),
previous stroke or TIA (OR, 0.052, 95% CI: 0.008–0.331, P = 0.002)
and persistent or permanent AF (OR, 0.332, 95% CI: 0.129–0.856, P =
Many previous studies have demonstrated that CHADS2 score was a
very useful and convenient scoring system, which was widely used for
the stroke risk stratiﬁcation in the patients with non-valvular AF [3].
Recently, CHADS2 score has been found to be associated with an
increased risk of AF recurrence following RFCA and LA or LAA thrombus
formation in AF patients [4,5]. In our present study, although thrombus
group have a higher CHADS2 score, multivariate logistic regression
analysis indicated that there is no statistical signiﬁcance. The patients
with severe stroke complications and acute HF were excluded from
our study, and calculated CHADS2 score may be lower than non-
valvular AF patients in “real world”.
In the present study,we demonstrated that low levels of HDL-C, LAD,
previous stroke or TIA and persistent or permanent AF were the inde-
pendent predictors of LA or LAA thrombus formation in non-valvular
AF patients. Several previous studies have proved a relationship
between low levels of HDL-C and the incidence or prevalence of AF [6,
7]. In addition, Watanabe H et al. enrolled 28,449 individuals without
AF from annual health examinations in Japan, after a follow-up of
4.5 ± 2.7 years, they demonstrated that low HDL-C was associated
with the development of AF in women (HR, 2.86; 95% CI: 1.49–5.50),
but not in men [8]. Although the results are rather confusing, it seems
to be true that the “cholesterol paradox” does exist between lipid
proﬁles and AF [9,10]. Suzuki S said that “inﬂammation might explain
the inverse relationship” [9], and Feminòthe R holds that “cholesterol
paradox in AF” may indicate a chronic inﬂammatory status induced by
a high level of circulating endotoxins and low levels of lipoproteins
[10]. We think that chronic inﬂammatory status may increase the risk
of LA or LAA thrombus formation in non-valvular AF patients.
In conclusion, it is noteworthy that the cholesterol paradox in AF is
still unclear. Therefore, further investigation is necessary to make clear
the complex mechanisms of the cholesterol paradox in AF, and also
the relationship between low levels of HDL-C and LA or LAA thrombus
in non-valvular AF patients.
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Table 1
Baseline characteristics of non-valvular AF patientswith andwithout left atrial or left atrial
appendage thrombus.
Thrombus
group
Non-thrombus
group
P
(n = 39) (n = 149)
Clinical characteristics
Age (years) 61.34 ± 9.15 59.13 ± 11.26 0.202
Male (n, %) 24 (61.5) 84 (56.4) 0.562
BMI (kg/m2) 26.72 ± 3.53 25.69 ± 3.31 0.089
BMI ≥ 25 kg/m2 (n, %) 26 (66.7) 82 (55.0) 0.191
Smoking (n, %) 16 (41.0) 57 (38.3)⁎ 0.752
Hypertension (n, %) 29 (74.4) 98 (65.8) 0.308
Diabetes mellitus (n, %) 5 (12.8) 34 (22.8) 0.170
Previous stroke or TIA (n, %) 12 (30.8) 9 (6.0)⁎⁎ b0.001
Peripheral vascular disease (n, %) 6 (15.4) 5 (3.4)⁎⁎ 0.004
Persistent or permanent AF (n, %) 16 (41.0) 25 (16.8)⁎⁎ 0.001
Mean duration of AF (years) 4.51 ± 3.90 5.20 ± 5.59 0.473
Platelets (×109/l) 212.08 ± 40.55 213.83 ± 55.53 0.854
UA (μmol/L) 345.92 ± 87.12 339.19 ± 90.90 0.682
FBG (mmol/l) 5.75 ± 0.87 6.24 ± 2.52 0.240
TC (mmol/l) 4.78 ± 1.11 4.73 ± 1.08 0.762
TG (mmol/l) 1.73 ± 1.09 1.64 ± 1.05 0.606
LDL-C (mmol/l) 3.04 ± 0.75 2.90 ± 0.85 0.362
HDL-C (mmol/l) 0.98 ± 0.22 1.15 ± 0.31⁎⁎ 0.001
CHADS2 score 1.56 ± 1.21 1.05 ± 1.01⁎⁎ 0.007
Echocardiogram
LAD (mm) 44.35 ± 6.17 39.85 ± 5.41⁎⁎ b0.001
LVEDD (mm) 48.33 ± 4.55 48.13 ± 5.46 0.842
LVESD (mm) 31.68 ± 4.77 31.22 ± 6.27 0.653
LVEF (%) 54.54 ± 7.22 58.88 ± 6.80⁎⁎ 0.001
Values are given as number of patients (%) or mean ± SD. AF = atrial ﬁbrillation; BMI =
body mass index; TIA = transient ischemic attack; UA = uric acid; FBG = fasting blood
glucose; TC = total cholesterol; TG = triglycerides; LDL-C = low-density lipoprotein
cholesterol; HDL-C = high-density lipoprotein cholesterol; LAD = left atrial diameter;
LVEDD = left ventricular end-diastolic diameter; LVESD = left ventricular end-systolic
diameter; LVEF = left ventricular ejection fraction.
⁎ P b 0.05.
⁎⁎ P b 0.01.
Table 2
Multivariate logistic regression analysis for thepotential risk factors of LA or LAA thrombus
in patients with AF.
β SE Waldχ2 P OR 95% CI
HDL-C −2.942 0.935 9.897 0.002 0.053⁎⁎ 0.008–0.330
LAD 0.107 0.043 6.150 0.013 1.113⁎ 1.023–1.210
LVEF −0.024 0.034 0.516 0.472 0.976 0.913–1.043
Persistent or
permanent AF
−1.102 0.483 5.201 0.023 0.332⁎ 0.129–0.856
Previous stroke or TIA −2.960 0.947 9.781 0.002 0.052⁎⁎ 0.008–0.331
Peripheral vascular
disease
−1.586 0.824 3.705 0.054 0.205 0.041–1.029
CHADS2 score −0.520 0.309 2.837 0.092 0.595 0.325–1.089
AF = atrial ﬁbrillation; LA = left atrial; LAA = left atrial appendage; BMI = body mass
index; TIA = transient ischemic attack; HDL-C = high-density lipoprotein cholesterol;
LAD = left atrial diameter; LVEF = left ventricular ejection fraction.
⁎ P b 0.05.
⁎⁎ P b 0.01.
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